CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Market News BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
News
13 Apr 2020

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

BERG, a clinical-stage biotech company that uses AI to research diseases and develop innovative treatments, has been awarded a spot in Frost & Sullivan's first-ever Frost Radar AI in Drug Discovery report in the pharmaceutical industry.

Frost & Sullivan's decision to recognize BERG as a biotech pioneer is based on its strong innovation trajectory, sustained growth over the last decade and being one of the first companies to develop corporate partnerships in this application.

BERG's capabilities also uniquely position the company to apply AI technologies to patient data to better understand the biological drivers of disease.

Amol Jadhav, Industry Analyst, Transformational Health, said: "Their inventive research efforts, understanding of diagnostics and drug development combined with the AI-powered approach have put them at the forefront of precision medicine."

Frost & Sullivan identified BERG as a Visionary in AI drug discovery for a number of reasons:

  • Innovative growth and early adoption of AI analytics has led BERG to powerful partnerships with AstraZeneca, Sanofi Pasteur, Genomics England and the DoD, where various projects from compound discovery to diagnostics and analytics to the development of medication adherence algorithms were completed.
  • The development of the proprietary platform, Interrogative Biology, that utilizes patient health data to identify areas where treatment could be introduced and identifying drug targets.
  • A healthy pipeline in clinical study developments, and currently in phase of clinical validation of its biomarker panel for oncology diagnosis and prognosis in Prostate, Pancreatic Cancer and Parkinson's disease.
  • An expansive portfolio of scientific publications, with over 650 issued in addition to being a leader among its competitors in pending patents.

    • Dr Niven R. Narain, BERG's President and Chief Executive Officer said they will continue to work with partners to identify "what's next" across multiple sectors including oncology, neurology and rare diseases.

    Related tags
    Market Research & Development
    Related categories
    Diagnostics Biopharmaceutical Services Drug Discovery Contract Development and Manufacturing Organisations (CDMOs) and Contract Manufacturing Organisations (CMOs) Technology and Software

    Related News